- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Advanced Enzyme Technologies (ADVENZYMES) kicked off Q1 FY26 strong with record revenue of ₹185.9 Cr (+20% YoY) and PAT of ₹40.4 Cr (+16% YoY), achieving 30% EBITDA margins. Growth was primarily driven by Human Healthcare (+21% YoY) and Animal Healthcare (+51% YoY). Management anticipates maintaining mid-double-digit growth for the year with gross margins around 73-75%. A new subsidiary, Advanced Nutrazyme Private Limited, was established for nutrition and wellness products. The new R&D facility is expected by Q4 FY26. The company is absorbing current US tariffs and remains cautiously optimistic on its growth trajectory.